What is Geneius Biotechnology's T-cell therapy?

Geneius Biotechnology develops autologous, adoptive T-cell therapies that re-educate a patient's natural T cells to attack multiple tumor-specific antigens that the immune system had previously overlooked. This is done through the company's Targeted DiversiTy™ platform without genetic engineering.

What clinical results has Geneius Biotechnology achieved?

An academic-sponsored proof-of-concept study using the same T cells produced by Geneius showed a 70% Overall Response Rate (ORR) and a 50% Complete Response (CR) rate, with complete remissions sustained at 5 years for half of those patients — and without significant toxicities.

How does Geneius T-cell therapy compare to CAR-T?

Geneius's natural T-cell therapy costs approximately 1/8th of CAR-T therapy, can be administered by community oncologists, causes only mild flu-like symptoms as side effects, and has shown efficacy in solid tumors — an area where CAR-T has not demonstrated clinical effectiveness.

What is the SMAR-T™ manufacturing process?

SMAR-T™ is Geneius Biotechnology's GMP manufacturing process. From 100 ml of a patient's blood, peripheral blood mononuclear cells (PBMCs) are collected and pulsed with antigenic peptides to generate 4 billion cells. These T cells are grown in a proprietary cytokine cocktail over 4 weeks until they reach the quantity and specificity needed for infusion.

Home | Geneius

Transforming Cancer Treatment

Next-generation T-cell immunotherapy.

Precision Immunotherapy

Re-educating the immune system.

Advancing Biotechnology

Innovation tailored to every patient.

Immunotherapy · Oncology

Advancing T-cell therapies
against cancer

GENEIUS is focused on the development & commercialization of innovative autologous, adoptive T-cell therapies, which offer a more robust immune response to cancer compared to current approaches.

Clinical evidence

Proven in
human trials

Clinical Efficacy in Human Trials
An academic sponsored, proof-of-concept study of the same T cells showed:

70 %

Overall Response Rate (ORR) in academic proof-of-concept study

50 %

Complete Response (CR) — with complete remissions at 5 years for half of those patients

In human, clinical trials. We believe that prior academic results, as well as our preclinical and manufacturing data suggest a high probability of success in Epstein-Barr Virus (EBV+) lymphoma.

Evidence of efficacy in solid tumors

Efficacy in solid tumors Durable response rates Without significant toxicities in lymphoma Efficacy in lymphoma Highly durable responses

Have been demonstrated in proof-of-concept clinical studies by academic centers in humans using natural T cells, like those produced by Geneius, by attacking a viral antigen associated with cancer. In contrast, CAR-T cells have not shown evidence of clinical effectiveness for solid tumors.

Patient Benefits

Mild Flu-Like Symptoms are the
Only Side Effect

Patients treated with natural T cells, like those produced by Geneius , experience only mild flu-like symptoms as a side effect.

Reasonable Cost

Cost is reasonable at 1/8th that of CAR-T .

Accessibility

Community oncologists can provide this treatment. The physician does not lose the revenue from the patient as with other protocols whose severe side effects require transfer to a major cancer center.

Consistency

For 90% of cancer patients , we meet our FDA release criteria when manufacturing T cells from a patient's blood draw. We expect to validate that T cells manufactured by our improved commercial process will be as effective as those in academic studies — giving us real potential to treat a far higher percent of patients than PD-1s like Keytruda or Opdivo.

Advancing T-cell therapies against cancer

Clinical Efficacy in Human Trials An academic sponsored, proof-of-concept study of the same T cells showed: